Devro PLC (LON:DVO) Gained Better Berenberg Rating; 5 Analysts Covering Curis, Inc. (CRIS)

Devro PLC (LON:DVO)‘s rating was upgraded by stock analysts at Berenberg to a Hold. They have a target of GBX 198.00 on DVO. Berenberg’s target gives a potential upside of 6.05% from the stock’s last close price.

Among 6 analysts covering Curis (NASDAQ:CRIS), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Curis has $7.0 highest and $5 lowest target. $5.75’s average target is 1061.62% above currents $0.495 stock price. Curis had 8 analyst reports since August 10, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, November 9 by Roth Capital. Guggenheim initiated the shares of CRIS in report on Monday, October 23 with “Buy” rating. The rating was downgraded by Zacks to “Sell” on Monday, September 21. The rating was initiated by FBR Capital with “Outperform” on Tuesday, August 11. The firm has “Buy” rating by TH Capital given on Monday, November 9. On Tuesday, September 1 the stock rating was downgraded by Zacks to “Hold”. See Curis, Inc. (NASDAQ:CRIS) latest ratings:

06/12/2017 Broker: Cowen & Co Rating: Buy
23/10/2017 Broker: Guggenheim Rating: Buy New Target: $7.0 Initiate

Among 10 analysts covering Devro PLC (LON:DVO), 2 have Buy rating, 0 Sell and 8 Hold. Therefore 20% are positive. Devro PLC has GBX 383 highest and GBX 180 lowest target. GBX 234.56’s average target is 17.77% above currents GBX 199.1741 stock price. Devro PLC had 46 analyst reports since July 27, 2015 according to SRatingsIntel. The stock of Devro plc (LON:DVO) earned “Hold” rating by Shore Capital on Wednesday, January 11. The stock has “Hold” rating by Societe Generale on Thursday, August 4. The stock of Devro plc (LON:DVO) earned “Hold” rating by Shore Capital on Tuesday, February 27. The company was maintained on Tuesday, January 19 by Investec. Peel Hunt maintained Devro plc (LON:DVO) on Tuesday, February 27 with “Hold” rating. The stock has “Hold” rating by N+1 Singer on Wednesday, April 26. The firm has “Neutral” rating by BNP Paribas given on Friday, November 11. The firm earned “Neutral” rating on Monday, July 27 by BNP Paribas. The stock of Devro plc (LON:DVO) has “Hold” rating given on Wednesday, December 13 by Numis Securities. Numis Securities upgraded it to “Add” rating and GBX 352 target in Monday, March 7 report.

Devro plc, together with its subsidiaries, makes and supplies collagen casings in the Americas, Europe, and the Asia-Pacific. The company has market cap of 332.32 million GBP. It offers edible and non-edible collagen casings, tubular films, and plastic casings for use in the production of a range of sausages and other meat products. It has a 21.42 P/E ratio. The firm sells its products to food manufacturers through agents and distributors under the Devro, Cutisin, Edicol, and Ralex names.

The stock increased 1.21% or GBX 2.3741 during the last trading session, reaching GBX 199.1741. About 170,480 shares traded. Devro plc (LON:DVO) has 0.00% since March 1, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock increased 2.04% or $0.01 during the last trading session, reaching $0.495. About 746,182 shares traded. Curis, Inc. (NASDAQ:CRIS) has risen 2.47% since March 1, 2017 and is uptrending. It has underperformed by 14.23% the S&P500.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $81.17 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

Investors sentiment decreased to 1.48 in 2017 Q3. Its down 0.04, from 1.52 in 2017Q2. It fall, as 14 investors sold Curis, Inc. shares while 15 reduced holdings. 13 funds opened positions while 30 raised stakes. 76.32 million shares or 4.90% more from 72.75 million shares in 2017Q2 were reported. Ameriprise Finance holds 42,900 shares or 0% of its portfolio. Wells Fargo And Co Mn has invested 0% in Curis, Inc. (NASDAQ:CRIS). State Bank Of New York Mellon Corp reported 363,101 shares. First Republic Inv Mgmt invested in 0% or 12,950 shares. Morgan Stanley stated it has 240,463 shares or 0% of all its holdings. Northern Trust Corporation, Illinois-based fund reported 1.34M shares. Meridian Inv Counsel accumulated 10,000 shares or 0.01% of the stock. Vident Invest Advisory Limited Company invested 0.05% in Curis, Inc. (NASDAQ:CRIS). Nationwide Fund reported 65,147 shares. Bnp Paribas Arbitrage Sa holds 0% or 11,453 shares. State Common Retirement Fund holds 0% or 101,500 shares in its portfolio. Grp Inc One Trading Limited Partnership has invested 0% in Curis, Inc. (NASDAQ:CRIS). Cormorant Asset Management Limited Liability Corp stated it has 1.15M shares or 0.3% of all its holdings. Royal Bank & Trust Of Canada owns 920,324 shares for 0% of their portfolio. Ameritas Prtnrs has invested 0% in Curis, Inc. (NASDAQ:CRIS).